379 related articles for article (PubMed ID: 3280680)
1. Transforming growth factor-beta 1 (TGF-beta 1) and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-beta 1 and TGF-beta 2, and recombinant human TGF-beta 1.
Espevik T; Figari IS; Ranges GE; Palladino MA
J Immunol; 1988 Apr; 140(7):2312-6. PubMed ID: 3280680
[TBL] [Abstract][Full Text] [Related]
2. Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells.
Kasid A; Bell GI; Director EP
J Immunol; 1988 Jul; 141(2):690-8. PubMed ID: 3133414
[TBL] [Abstract][Full Text] [Related]
3. Lymphokine-activated effector cells: modulation of activity by cytokines.
Mehta S; Flanagan P; Blackinton D; Wanebo H
Lymphokine Cytokine Res; 1992 Apr; 11(2):73-7. PubMed ID: 1581419
[TBL] [Abstract][Full Text] [Related]
4. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
[TBL] [Abstract][Full Text] [Related]
5. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.
Owen-Schaub LB; Gutterman JU; Grimm EA
Cancer Res; 1988 Feb; 48(4):788-92. PubMed ID: 3257408
[TBL] [Abstract][Full Text] [Related]
6. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
Mulé JJ; Krosnick JA; Rosenberg SA
J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
[TBL] [Abstract][Full Text] [Related]
7. Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2.
Harthun NL; Weaver AM; Brinckerhoff LH; Deacon DH; Gonias SL; Slingluff CL
J Immunother; 1998 Mar; 21(2):85-94. PubMed ID: 9551359
[TBL] [Abstract][Full Text] [Related]
8. Tumor targets stimulate IL-2 activated killer cells to produce interferon-gamma and tumor necrosis factor.
Chong AS; Scuderi P; Grimes WJ; Hersh EM
J Immunol; 1989 Mar; 142(6):2133-9. PubMed ID: 2493506
[TBL] [Abstract][Full Text] [Related]
9. Sequential TNF and TGF-beta regulation of expansion and induction of cytotoxicity in long-term cultures of lymphokine-activated killer cells.
Koberda J; Przepiorka D; Moser RP; Grimm EE
Lymphokine Cytokine Res; 1994 Apr; 13(2):139-45. PubMed ID: 8061115
[TBL] [Abstract][Full Text] [Related]
10. TGF beta down-regulates TLiSA1 expression and inhibits the differentiation of precursor lymphocytes into CTL and LAK cells.
Jin B; Scott JL; Vadas MA; Burns GF
Immunology; 1989 Apr; 66(4):570-6. PubMed ID: 2541074
[TBL] [Abstract][Full Text] [Related]
11. IL-4 regulates IL-2 induction of lymphokine-activated killer activity from human lymphocytes.
Kawakami Y; Custer MC; Rosenberg SA; Lotze MT
J Immunol; 1989 May; 142(10):3452-61. PubMed ID: 2654291
[TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor-alpha enhances cytolytic activity of human natural killer cells.
Ostensen ME; Thiele DL; Lipsky PE
J Immunol; 1987 Jun; 138(12):4185-91. PubMed ID: 3108384
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers.
Nio Y; Zighelboim J; Berek JS; Bonavida B
Nat Immun Cell Growth Regul; 1990; 9(4):283-96. PubMed ID: 2215516
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of human B cell proliferation and differentiation by tumor necrosis factor-alpha and interleukin 1.
Jelinek DF; Lipsky PE
J Immunol; 1987 Nov; 139(9):2970-6. PubMed ID: 3117883
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of lymphokine-activated killer cell-mediated cytotoxicity by phorbol ester.
Nishimura T; Burakoff SJ; Herrmann SH
J Immunol; 1989 Mar; 142(6):2155-61. PubMed ID: 2646377
[TBL] [Abstract][Full Text] [Related]
16. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.
Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI
J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355
[TBL] [Abstract][Full Text] [Related]
17. Effects of biological response modifiers on lung natural killer activity.
Lauzon W; Lemaire I
Immunopharmacol Immunotoxicol; 1991; 13(3):237-50. PubMed ID: 1719060
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1.
Inge TH; Hoover SK; Susskind BM; Barrett SK; Bear HD
Cancer Res; 1992 Mar; 52(6):1386-92. PubMed ID: 1531782
[TBL] [Abstract][Full Text] [Related]
19. Differential regulation of interleukin-12- and interleukin-15-induced natural killer cell activation by interleukin-4.
Salvucci O; Mami-Chouaib F; Moreau JL; Thèze J; Chehimi J; Chouaib S
Eur J Immunol; 1996 Nov; 26(11):2736-41. PubMed ID: 8921963
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity of long-term cultured activated killer cells induced by anti-T3 antibody.
Yun YS; Hargrove ME; Ting CC
J Immunol; 1988 Aug; 141(4):1390-7. PubMed ID: 3260924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
